By S. Sutter A negative view by Swedish authorities appears to have been the last nail in the regulatory coffin for GlaxoSmithKline PLC’s global pursuit of a prostate cancer prevention indication for Avodart (dutasteride). The company announced March 23 that it will no longer pursue global approval of the 5-alpha reductase inhibitor for prostate cancer […]